758oselinexor (kpt-330), an Oral, Selective Inhibitor of Nuclear Export (sine) Shows Anti-prostate Cancer (prca) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-resistant Prostate Cancer (crpc).

Sorry, there's nothing here.

Cite this paper

@article{Mahaseth2014758oselinexorA, title={758oselinexor (kpt-330), an Oral, Selective Inhibitor of Nuclear Export (sine) Shows Anti-prostate Cancer (prca) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-resistant Prostate Cancer (crpc).}, author={Hemchandra Mahaseth and Sankar N. Maity and Nashat Y Gabrail and Amit Mahipal and J F Gericitano and Sharon Shacham and Tami Rashal and Boris S. Klebanov and Robert W. Carlson and Eran Shacham and Dascena Vincent and Marion Ewing Kauffman and Anthony Frank Shields and Mansoor Mirza and John Araujo}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2014}, volume={25 suppl_4}, pages={iv257} }